High-value dealmaking strengthens big pharma’s CNS ambitions Diseases of the central nervous system continue to catalyze dealmaking as companies search for new therapies to tackle some major unmet medical needs.
By Marcia Santos Sadler, August 5, 2022. Biosortia is busy mining, not Bitcoin but, Microbes. Biosortia is doing what works in a way nobody ever thought possible or scalable. By providing